Pancreatic ductal adenocarcinoma pancreatic ductal adenocarcinoma, pancreatic cancer, borderline resectable pancreatic cancer, locally advanced pancreatic cancer
Conditions
Interventions
Sponsors
Toyama Hirochika
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Histologically diagnosed pancreatic ducatal adenocarcinoma: including suspected case of adenocarcinoma by a cytology. - Anable to undergo dynamic computed tomography. - Radiologically diagnosed borderline resectable or locally advanced unresectable pancreatic ductal adenocarcinoma according to NCCN guideline 2018. - Age 20 - 75 - ECOG performance status 0 or 1 - No treatment history for pancreatic ductal adenocarcinoma. - No more than grade 1 peripheral sensory and motor neuropathy. - Good functional capacities of main organs within two weekes before enrollment. - Expected survival time more than 3 months. - Feasible for pancreatic resection. - With imformed written consent.
Exclusion criteria
Exclusion criteria: - Homozygous or double heterozygous fot UGT1A1*28, 6. - Bleeding disorders - Administration of steroid or immunosuppressive drug - Severe complication of main organs - Interstitial pneumonia, pulmonary fibrosis, or severe emphysema - Uncontrollable infectious disease - Uncontrollable diarrhea - Pregnancy - Double cancer with disease-free survival less than 5 years: excluding cured cutaneous basal cell cancer and gastrointestinal cancer with endoscopically curative resection. - Investigator judgement that the patient should not participate for any reason
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| R0 resectability | — |
Secondary
| Measure | Time frame |
|---|---|
| - Pancreatic resection - Relative dose intensity - Radiographically response rate - Overall Survival - Distant recurrence-free survival - Disease-free survival - Completion rate for 6 courses of FOLFIRINOX | — |
Contacts
Public ContactHirochika Toyama
Kobe University Hospital
Outcome results
None listed